非小细胞肺癌吉西他滨药物耐药相关基因研究进展

With the development of pharmacogenomics and pharmacogenetics, personal therapy based on genes has become one of the most effective ways to enhance chemotherapeutic effect on non-small cell lung cancer (NSCLC) patients. Much attention has been paid to validate the predictive biomarkers of chemothera...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000321/
https://www.ncbi.nlm.nih.gov/pubmed/21569648
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.05.08
Descripción
Sumario:With the development of pharmacogenomics and pharmacogenetics, personal therapy based on genes has become one of the most effective ways to enhance chemotherapeutic effect on non-small cell lung cancer (NSCLC) patients. Much attention has been paid to validate the predictive biomarkers of chemotherapy in order to guide chemotherapy and enhance effect in general. Gemcitabine is one of the common agents treating NSCLC recently. This review is mainly about the recent reports on potential biomarkers of Gemcitabine in tailored therapy of NSCLC.

Ejemplares similares